Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis

Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Sakthiswary, Rajalingham ^a,b   Chan, Grace Yin Lai ^a   Koh, Ee Tzun ^a   Leong, Khai Pang ^a   Thong, Bernard Yu Hor ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOSE RESPONSE; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PREDICTION; PREVALENCE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGAPORE; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADULT; AGED; ALANINE TRANSAMINASE; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS; SINGAPORE;

EID: 84902142389     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/823763     Document Type: Article

References (26)

1. Combe B., Landewe R., Lukas C., Bolosiu H. D., Breedveld F., Dougados M., Emery P., Ferraccioli G., Hazes J. M. W., Klareskog L., Machold K., Martin-Mola E., Nielsen H., Silman A., Smolen J., Yazici H., EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases 2007 66 1 34 45 2-s2.0-33846001961 10.1136/ard.2005.044354 (Pubitemid 46044858)
2. Saag K. G., Gim G. T., Patkar N. M., Anuntiyo J., Finney C., Curtis J. R., Paulus H. E., Mudano A., Pisu M., Elkins-Melton M., Outman R., Allison J. J., Almazor M. S., Bridges S. L. Jr., Chatham W. W., Hochberg M., Maclean C., Mikuls T., Moreland L. W., O'Dell J., Turkiewicz A. M., Furst D. E., American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care and Research 2008 59 6 762 784 2-s2.0-45349090538 10.1002/art.23721 (Pubitemid 351847559)
3. Salliot C., van der Heijde D., Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Annals of the Rheumatic Diseases 2009 68 7 1100 1104 2-s2.0-67549107120 10.1136/ard.2008.093690
4. van Ede A. E., Laan R. F., Blom H. J., The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis and Rheumatism 2001 44 11 2525 2530 (Pubitemid 33049330)
5. Quintin E., Scoazec J.-Y., Marotte H., Miossec P., Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Research and Therapy 2010 12 4, article R143 2-s2.0-77954547170 10.1186/ar3085
6. Penalva Polo J. C., Gómez Andrés A., Vela P., Niveiro M., Acute liver failure in a patient with methotrexate therapy. Revista Espanola de Enfermedades Digestivas 2002 94 7 440 441 2-s2.0-0036628663 (Pubitemid 34982248)
7. Hakim N. S., Kobienia B., Benedetti E., Bloomer J., Payne W. D., Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. International Surgery 1998 83 3 224 225 2-s2.0-0032106673 (Pubitemid 128463243)
8. Chalasani N., Younossi Z., Lavine J. E., Diehl A. M., Brunt E. M., Cusi K., Charlton M., Sanyal A. J., The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012 55 6 2005 2023 2-s2.0-84861543083 10.1002/hep.25762
9. Rau R., Karger T., Herborn G., Frenzel H., Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. The Journal of Rheumatology 1989 16 4 489 493 2-s2.0-0024315515 (Pubitemid 19149407)
10. Adams L. A., Angulo P., Treatment of non-alcoholic fatty liver disease. Postgraduate Medical Journal 2006 82 967 315 322 2-s2.0-33645536593 10.1136/pgmj.2005.042200 (Pubitemid 43780662)
11. van Ede A. E., Laan R. F. J. M., Blom H. J., de Abreu R. A., van de Putte L. B. A., Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Seminars in Arthritis and Rheumatism 1998 27 5 277 292 2-s2.0-0031950185 10.1016/S0049-0172(98)80049-8 (Pubitemid 28176234)
12. Kremer J. M., Galivan J., Streckfuss A., Kamen B., Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis and Rheumatism 1986 29 7 832 835 2-s2.0-0022547880 (Pubitemid 16072880)
13. Ranganathan P., Eisen S., Yokoyama W. M., McLeod H. L., Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Annals of the Rheumatic Diseases 2003 62 1 4 9 2-s2.0-0037215239 10.1136/ard.62.1.4 (Pubitemid 36005787)
14. Urano W., Taniguchi A., Yamanaka H., Tanaka E., Nakajima H., Matsuda Y., Akama H., Kitamura Y., Kamatani N., Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002 12 3 183 190 2-s2.0-0036263469 10.1097/00008571-200204000-00002 (Pubitemid 34596782)
15. Mehta S. R., Thomas E. L., Bell J. D., Johnston D. G., Taylor-Robinson S. D., Non-invasive means of measuring hepatic fat content. World Journal of Gastroenterology 2008 14 22 3476 3483 2-s2.0-50849087307 10.3748/wjg.14.3476
16. Foster T., Anania F. A., Li D., Katz R., Budoff M., The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). Digestive Diseases and Sciences 2013 58 8 2392 2398 2-s2.0-84881393394 10.1007/s10620-013-2652-7
17. Niaz A., Ali Z., Nayyar S., Fatima N., Prevalence of NAFLD in healthy and young male individuals. ISRN Gastroenterology 2011 2011 4 10.5402/2011/363546 363546
18. Visser K., van der Heijde D. M. F. M., Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clinical and Experimental Rheumatology 2009 27 6 1017 1025 2-s2.0-76649094231
19. Walker A. M., Funch D., Dreyer N. A., Tolman K. G., Kremer J. M., Alarcon G. S., Lee R. G., Weinblatt M. E., Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis and Rheumatism 1993 36 3 329 335 2-s2.0-0027523650 (Pubitemid 23090599)
20. Cáliz R., del Amo J., Balsa A., Blanco F., Silva L., Sanmarti R., Martnez F. G., Collado M. D., Del Carmen Ramirez M., Tejedor D., Artieda M., Pascual-Salcedo D., Oreiro N., Andreu J. L., Graell E., Simon L., Martínez A., Mulero J., The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scandinavian Journal of Rheumatology 2012 41 1 10 14 2-s2.0-84856410726 10.3109/03009742.2011.617312
21. Malik F., Ranganathan P., Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics 2013 14 3 305 314 2-s2.0-84873675683 10.2217/pgs.12.214
22. Owen S. A., Lunt M., Bowes J., Hider S. L., Bruce I. N., Thomson W., Barton A., MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics Journal 2013 13 2 137 147 2-s2.0-84875446205 10.1038/tpj.2011.42
23. Gaiani S., Avogaro A., Bombonato G. C., Bolognesi M., Amor F., Vigili de Kreutzenberg S., Guarneri G., Sacerdoti D., Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: prevalence and relationships with hemodynamic alterations detected with Doppler sonography. Journal of Ultrasound 2009 12 1 1 5 2-s2.0-61649104775 10.1016/j.jus.2008.12.002
24. Ortiz-Lopez C., Lomonaco R., Orsak B., Finch J., Chang Z., Kochunov V. G., Hardies J., Cusi K., Prevalence of prediabetes and diabetes and metabolic profile of patients with Nonalcoholic Fatty Liver Disease (NAFLD). Diabetes Care 2012 35 4 873 878 2-s2.0-84859393575 10.2337/dc11-1849
25. Curtis J. R., Beukelman T., Onofrei A., Cassell S., Greenberg J. D., Kavanaugh A., Reed G., Strand V., Kremer J. M., Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Annals of the Rheumatic Diseases 2010 69 1 43 47 2-s2.0-73449096104 10.1136/ard.2008.101378
26. Kremer J. M., Genovese M. C., Cannon G. W., Caldwell J. R., Cush J. J., Furst D. E., Luggen M. E., Keystone E., Weisman M. H., Bensen W. M., Kaine J. L., Ruderman E. M., Coleman P., Curtis D. L., Kopp E. J., Kantor S. M., Waltuck J., Lindsley H. B., Markenson J. A., Strand V., Crawford B., Fernando I., Simpson K., Bathon J. M., Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 2002 137 9 726 733 2-s2.0-0037027427 (Pubitemid 35265316)